ArticleJournal of natural medicines2026
Total flavonoids from Carthamus tinctorius L. inhibit the liver fibrosis progression via Hippo/YAP pathway.
Article in Journal of natural medicines, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Total Flavonoids fromInternational journal of molecular sciences · 2026Article
- Recent Advances in the Study of Traditional Chinese Medicine in Reversing Hepatic Fibrosis Through the Regulation of Hepatic Stellate Cells Apoptosis Pathways.Drug design, development and therapy · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Liver fibrosis is a significant global health threat, and Carthamus tinctorius L., a traditional herb used for liver ailments, contains flavonoids with diverse pharmacological properties. This study explored the effects and mechanisms of total flavonoids from Carthamus tinctorius L. (TFCTL) on hepatic fibrosis in mice and TGF-β1-induced activation of hepatic stellate cells (HSCs). Using LC-MS/MS, TFCTL's composition was characterized, and models of liver fibrosis in mice and HSC-T6 cell activation in vitro were established. Techniques such as CCK-8, Western blotting, RT-qPCR, and immunofluorescence revealed that TFCTL inhibited HSC-T6 activation and proliferation by promoting YAP phosphorylation and degradation via increased MST1 and LATS1 expression, suppressing Hippo pathway target genes. TFCTL also improved liver fibrosis pathology in mice, primarily through the Hippo/YAP pathway. These results underscore the anti-fibrotic potential of TFCTL, establishing it as a highly promising candidate for the treatment of liver fibrosis.
Indexed as
Identifiers
41652272What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.